Biosimilars slated for 12 years market exclusivity

Share this article:
In a move applauded by brand name manufacturers, the Senate Health, Education, Labor and Pensions Committee and its House counterpart voted in July to support 12 years market exclusivity for biologic innovators under a follow-on biologics (biosimilars) provision attached to its healthcare reform bill.

It now awaits passage in each chamber, reconciliation in a conference and final votes after the August recess.
“The language approved … strikes the appropriate balance among ensuring patient safety, expanding competition, reducing costs and providing necessary and fair incentives that will provide for continued biomedical breakthroughs,” said Biotechnology Industry Organization president Jim Greenwood.

Both committers had “embraced our long-held belief that a minimum of 12 years of data exclusivity establishes a fair and reasonable period to ensure continued biomedical innovation and provide the benefits of competition,” he said. 

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"